

Positron Emission Tomographic Scan Investigations of Huntington's Disease: Cerebral Metabolic Correlates of Cognitive Function

Stanley Berent, PhD,*†‡ Bruno Giordani, PhD,*‡ Shirley Lehtinen, MA,* Dorene Markel, MS,†
John B. Penney, MD,† H. A. Buchtel, PhD,*‡§ Simon Starosta-Rubinstein, MD,† Richard Hichwa, PhD,§
and Anne B. Young, MD, PhD†

Fifteen drug-free patients with early to mid-stage Huntington's disease (HD) were evaluated with positron emission tomographic (PET) scans of ^{18}F -2-fluoro-2-deoxy-D-glucose uptake and quantitative measures of neurological function, learning, memory, and general intelligence. In comparison with a group of normal volunteers, the HD patients showed lower metabolism in both caudate ($p < 0.001$) and putamen ($p < 0.001$) on PET scans. A significant and positive relationship was found between neuropsychological measures of verbal learning and memory and caudate metabolism in the patient group but not in the normal group. Visual-spatial learning did not reflect a similar pattern, but performance intelligence quotient was positively related to both caudate and putamen metabolism in the HD group. Vocabulary level was unrelated to either brain structure. Discussion focuses on these and other observed brain-behavior relationships and on the implications of these findings for general behaviors such as those involved in coping and adaptation.

Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, Starosta-Rubinstein S, Hichwa R, Young AB. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. *Ann Neurol* 1988;23:541-546

Huntington's disease (HD) is a dominantly inherited disorder that usually starts about age 40 years and progresses over a 10- to 30-year period [16, 21]. Early neurological signs of the disease include chorea, decreased fine motor coordination, and slowed saccadic eye movements [9, 11, 23-25, 32]. Behavioral signs that occur later in the progression of the disease include dysarthria, rigidity, bradykinesia, and dystonia [9, 11, 23-25, 32].

There is substantial evidence that as HD develops, there is corresponding and progressive neuronal loss, increased cognitive impairment, and worsening capacity to perform the activities of daily living. Pathologically, HD is characterized by marked neuronal loss in the caudate nucleus and putamen [5, 15, 30] but few or no cortical abnormalities [30]. The general behavioral decline in HD has been evaluated using standardized rating scales of functional capacities [9, 11, 23-25, 31, 32]. Less is known, however, about the specific cognitive impairments that possibly subserve these more general disabilities. The documented cog-

nitive impairment in HD appears to proceed in a regular fashion that mirrors the physiological deterioration [6, 7].

Until recently, there has been little opportunity to study the relationships that might exist between observed behavior and underlying physiological processes. With the advent of positron emission tomographic (PET) techniques, however, a direct comparison between behavior, metabolism, and structural integrity of the nervous system has become possible. Studies with PET have already revealed a significant reduction in caudate metabolism in patients with early HD who show little or no atrophy as measured structurally by computed x-ray tomography (CT) [12, 13, 31]. Other studies have examined patients in various stages of their illness to investigate the relationship between brain metabolism and neurological features [13, 14, 19]. In earlier work [31], we demonstrated a relationship between metabolism and functional aspects of behavior that, it was hypothesized, would be directly related to the function of the area of the brain being

From the Departments of *Psychiatry, †Neurology, and ‡Psychology, and the §Division of Nuclear Medicine, University of Michigan, and the †Veterans Administration Medical Center, Ann Arbor, MI.

Received Sep 2, 1987, and in revised form Oct 30 and Dec 7. Accepted for publication Dec 7, 1987.

Address correspondence to Dr Berent, 480 Med Inn Bldg, University of Michigan Hospitals, Ann Arbor, MI 48109-0840.

imaged. Using this approach, it was possible to demonstrate that reductions in metabolism could be detected with PET before structural changes in brain could be measured using CT. We also presented observations on general behavioral efficiency and neurological signs. The present work focuses on cognitive abilities such as verbal and visual learning and seeks to relate these variables to the metabolic function in regions of brain that are known to be affected in HD.

Materials and Methods

Fifteen patients with the diagnosis of adult-onset HD were scheduled for 2 days of examinations. Diagnoses were determined by family history and physical examination. Informed consent was obtained following a full explanation of the procedures to be undertaken. All studies reported here were done at least 1 month after discontinuation of any medications. During a 2-day period, each patient received a PET scan using ^{18}F -2-fluoro-2-deoxy-D-glucose (^{18}F -FDG). In addition, each patient received a quantitative neurological examination and evaluation for functional capacity, as described previously [31], and a neuropsychological evaluation using standardized psychometric techniques.

Patients ranged in age from 25 to 60 years (mean age = 40.5 years). Fourteen normal volunteers ranged from 25 to 65 years (mean age = 37.5 years). Patients included in these studies were in stages I (5 patients), II (9 patients), or III (1 patient) of HD as defined by the Shoulson and Fahn scale [26]. This scale characterizes patients in terms of symptom severity, with stage I being the least severe and stage III being moderately severe.

All patients were scanned on a Cyclotron Corporation PCT 4500A tomograph (a 3-ring, 5-slice, 96-detector/ring tomograph) according to previously described techniques [31]. The spatial resolution of the scanner was 11 mm in the x-y plane and 8.8 mm in the z plane. Metabolic data from each scan were analyzed by a technique described in detail elsewhere [31]. All patients were positioned in the scanner so that the slices were parallel to the canthomeatal line. Briefly, the slice corresponding to 0° section, number 8 or 9 from the CT atlas of Matsui and Hirano [17], was analyzed in detail for each patient. In cases where two sections appeared equally to approximate this slice, data were obtained on both slices and averaged. Cross-sectional histograms were obtained as follows: (1) the caudate nucleus (halfway between the rostral edge of the thalamus and the frontal cortex anterior to the ventricles); (2) the putamen (halfway between the caudate cross-section and the rostral edge of the thalamus); and (3) the middle of the thalamus. By inspection of the cross-sectional histograms, it was possible to observe the maximum glucose metabolic rate over the head of the caudate in all the normal volunteers and the HD patients. Although caudate metabolism in some of the patients was very low, there was an indication of a shoulder on the cross-sectional histogram that allowed the determination of caudate metabolism at the inflection of the curve [31]. Values of caudate, putamen, and thalamus local cerebral metabolic rate for glucose (LCMRGlc) were taken as an average of data from 1×3 pixel regions of interest (ROIs) on a 64×64 pixel matrix reconstruction of the PET scan data. Values associ-




Fig 1. Positron emission tomograph of a normal volunteer.




Fig 2. Positron emission tomograph of a patient with Huntington's disease, stage II.

ated with each of the ROIs were normalized to the cortical values at the same level as the ROI, as in our previous work [31]. Figures 1 and 2 show PET scans for a normal volunteer and for an HD patient, respectively. Four of the 15 patients had mild to moderate caudate atrophy on CT scan [31], but the method of estimating peak caudate metabolism by the histogram technique minimizes partial volume problems.

The psychological test scores used in this work were

Table 1. Comparison of Metabolic Activity and Psychological Test Scores for Huntington's Disease Patients and Age-matched Normal Controls

Variable	HD Patients		Normal Subjects		Significance ^a
	Mean	(SD)	Mean	(SD)	
Age (yrs)	40.5	(10.30)	37.5	(13.30)	NS
ICMRGlc ^b					
Caudate/cortex	0.47	(0.19)	0.91	(0.10)	<0.01
Putamen/cortex	0.59	(0.21)	1.05	(0.07)	<0.01
Thalamus/cortex	1.08	(0.15)	0.99	(0.11)	NS
WMS					
MQ	94.00	(13.70)	127.00	(11.50)	<0.01
Verbal learning (VII)	13.17	(3.30)	19.83	(1.30)	<0.01
Visual learning (VI)	7.60	(2.80)	12.80	(1.50)	<0.01
WAIS-R					
FSIQ	86.20	(10.60)	116.18	(13.20)	<0.01
PIQ	84.58	(10.00)	113.90	(15.10)	<0.01
Vocabulary	8.00	(1.50)	12.08	(2.30)	<0.01
Digit symbol	4.90	(1.90)	11.00	(2.90)	<0.01

^aSignificance expressed as *p* values for *t* test of Huntington's disease patients versus normal controls.

^bValues of peak metabolic activity in the caudate, putamen, and thalamus were each normalized to cortical metabolism at the same level (as assessed by 1 × 3 pixel regions of interest on the histogram) [31].

HD = Huntington's disease; SD = standard deviation; ICMRGlc = local cerebral metabolic rate for glucose; WMS = Wechsler Memory Scale; WAIS-R = Wechsler Adult Intelligence Scale—Revised; FSIQ = full-scale intelligence quotient; NS = not significant.

derived from commercially available and standardized instruments and include the Wechsler Memory Scale—Form I (WMS) and the Wechsler Adult Intelligence Scale—Revised (WAIS-R). This work focused on aspects of learning and memory in patients with HD. Two subtests were chosen from the WMS for specific comparisons between the HD patients and normal controls—immediate recall on subtest VI as an index of visual learning and subtest VII as a measure of verbal learning. The WMS summary score, MQ, was also completed by employing a modified but standard system [20, 29]. The Full Scale Intelligence Quotient (IQ) from the WAIS-R was also estimated using a standard prorating formula [27]. Two scales of the WAIS-R were chosen for analyses. These were the age-corrected vocabulary score and the digit symbol subtest. These scales provided an additional measure of verbal performance and visual psychomotor performance, respectively. In all cases, tests were administered in standard fashion by trained technicians who were unaware of the patient's specific clinical or PET-metabolic classification.

Data from scans, clinical evaluations, and psychometrics were entered into the University of Michigan's computer terminal system (MTS), and the system's Amdahl 5860 was used in conjunction with the investigators' laboratory microcomputers for statistical analyses. In addition to simple description, these analyses included Pearson product-moment correlations and standard *t* tests. The continuous and normally distributed nature of the psychometrically derived data in these studies allowed the use of these parametric statistical procedures.

Results

As pointed out in previous work [31], compared with normal control subjects, the HD group had signifi-

cantly lower metabolic activity of ¹⁸F-FDG in the caudate and putamen nuclei but not in the thalamus (see Figs 1 and 2 and Table 1). Although the control subjects were younger as a group than the HD patients, the difference in age was not significant. The control subjects had significantly higher general intellectual ability as measured by the WAIS-R than the HD patients. Approximately 30% of the HD patients and 80% of the normal volunteers had received education beyond the high school level. Although eighty percent of the HD patients completed at least 12 years of schooling, the control subjects had higher education levels (mean = 14.8 years, SD = 2.2) than the HD patients (mean = 12.3 years, SD = 1.9) (*t* = 3.09; *p* < 0.01).

Correlational relationships between PET measures and neuropsychological test results are presented in Table 2. The relationship between ¹⁸F-FDG metabolism and MQ was significant only for the caudate nucleus in the HD patients. Although the magnitude of the relationship in the putamen and thalamus could be considered a trend in these patients, there appeared to be no functional relationship between these areas of brain and memory in the normal volunteers.

The relationship between WMS scores and caudate metabolism was very strong for verbal (paired-associate) learning. No significant relationship was observed between visual-spatial learning on this test (i.e., WMS) and metabolism in the basal ganglia. No significant relationship was found between the vocabulary score on the WAIS-R (a measure of general verbal ability but one that is different from that reflected in

Table 2. Comparison of Local Cerebral Metabolic Rates for Glucose for Huntington's Disease Patients and for Normal Volunteers

Comparison	HD Patients		Normal Subjects	
	r	p	r	p
Caudate to				
WMS, MQ	+0.67	<0.01	-0.07	NS
Verbal (VII)	+0.73	<0.01	-0.38	NS
Visual (VI)	-0.04	NS	+0.39	NS
FSIQ	+0.46	NS	-0.01	NS
PIQ	+0.70	<0.05	-0.12	NS
Vocabulary	+0.19	NS	-0.31	NS
Digit Symbol	+0.79	<0.01	-0.45	NS (0.14)
Putamen to				
WMS, MQ	+0.50	NS (0.07)	-0.13	NS
Verbal (VII)	+0.50	NS (0.06)	-0.48	NS (0.11)
Visual (VI)	+0.02	NS	+0.28	NS
FSIQ	+0.38	NS	-0.10	NS
PIQ	+0.66	<0.05	-0.35	NS
Vocabulary	+0.30	NS	-0.12	NS
Digit Symbol	+0.85	<0.01	-0.68	<0.01
Thalamus to				
WMS, MQ	+0.41	NS	-0.16	NS
Verbal (VII)	+0.47	NS (0.09)	+0.05	NS
Visual (VI)	+0.20	NS	-0.53	NS (0.07)
FSIQ	+0.33	NS	-0.26	NS
PIQ	+0.06	NS	-0.25	NS
Vocabulary	+0.02	NS	+0.18	NS
Digit Symbol	+0.02	NS	-0.07	NS
Caudate to Putamen	+0.91	<0.01	+0.70	<0.01
Caudate to Thalamus	-0.21	NS	-0.41	NS
Putamen to Thalamus	-0.32	NS	-0.16	NS

r = Pearson product-moment correlation coefficient; p = significance level; NS = not significant; WMS = Wechsler Memory Scale; WMS FSIQ = full-scale intelligence quotient.

the WMS) and metabolism in these same areas of brain.

A significant correlation was found between both normalized caudate and putamen ICMRGlc and performance on the digit symbol subtest of the WAIS-R. For the putamen, this relationship held for the normal subjects as well as the HD patients. However, the nature of the relationship appeared to be quite different for the two groups. In HD patients there was a positive relationship between metabolism and accurate performance on this test, but in normal subjects there was an inverse relationship (i.e., higher relative metabolism was associated with poorer performance).

Table 3 presents additional relationships between quantitative neurological and psychometric observations.

Discussion

These findings are consistent with the hypothesis that cognitive impairment in HD reflects functional deteri-

Table 3. Correlational Relationships between Behavioral Measures—Quantitative Neurological and Psychometric

Comparison	r _{x,y}	p
Resting Chorea to		
Verbal Learning (VII)	-0.53	<0.05
Visual Learning (VI)	+0.02	NS
WAIS-R, FSIQ	-0.02	NS
Vocabulary	+0.07	NS
Digit Symbol	-0.68	<0.01
Total Functional Capacity to		
Verbal Learning (VII)	+0.67	<0.01
Visual Learning (VI)	-0.09	NS
WAIS-R, FSIQ	+0.37	NS
Vocabulary	+0.23	NS
Digit Symbol	+0.75	<0.01
Rapid Alternating Movement to		
Verbal Learning (VII)	-0.58	<0.05
Visual Learning (VI)	-0.20	NS
WAIS-R, FSIQ	-0.37	NS
Vocabulary	-0.21	NS
Digit Symbol	-0.76	<0.01

r = Pearson product-moment correlation coefficient; p = significance level; NS = not significant; WAIS-R = Wechsler Adult Intelligence Scale—Revised; FSIQ = full-scale intelligence quotient.

oration of the neuroanatomical structures that subserve the affected abilities. The findings are more complex in their implications than they may at first seem, however. To the extent that these correlational observations reflect actual structural changes, they suggest specific, as well as general, effects of disease progression in HD. The HD patients as a group functioned below normal on all cognitive measures (in comparison with the normal control subjects in this study and in relation to published norms for the standardized tests). At the same time, different functional relationships appeared to exist between the structures of the brain that are affected in HD and the various abilities as measured here. For instance, the degree of hypometabolism of the caudate was found to have a strong correlation with performance on the verbal learning task but not with performance on the visual learning task. Furthermore, this relationship was specific to this structure of the basal ganglia, and no such relationship was evident for the thalamus or even the putamen. The absence of a significant relationship between the putamen and task performance is especially intriguing because metabolism itself was highly correlated between the caudate and the putamen. One might anticipate that they would both correlate with behavioral function, or dysfunction, but they do not.

If it is true that both general and specific abilities are adversely affected in HD, one might speculate that cortical, as well as subcortical, regions of brain are involved. From a neuropsychological point of view, Seidenberg and associates [22] have shown that general intelligence as measured by the WAIS-R corre-

lates very highly with basic cognitive abilities, as reflected in tasks such as the Halstead Test Battery. Such correlations in functional aspects of behavior could sensitively reflect functional connections that exist between the cortex and subcortical structures. From a direct functional metabolic point of view, Foster and associates [10] and Berent and associates [2] have presented data that support the hypothesis of cortical hypometabolism in subcortical dementia (progressive supranuclear palsy). Whether by way of structural changes or as a reflection of disorder on a functional level, it may be that diseased subcortical regions adversely affect cortical efficiency in these HD patients. It should be said, however, that whereas a disturbance of higher cortical functions might be invoked to explain the impairment of general intellectual ability in the population under study, subcortical regions alone can probably account for disorders in many specific cognitive functions.

The relationship between verbal learning and hypometabolism in the caudate nucleus was very specific. From a cognitive perspective, the abilities involved were not language or intelligence in general, since neither vocabulary level nor estimated full-scale IQ was found to show statistically significant correlations to regions of the basal ganglia. The finding was also specific to the HD group; no similar correlation was observed in the normal control group. Because verbal learning was found to correlate highly with other signs and symptoms of HD (e.g., decline in total functional capacity), one could query the role of this important cognitive ability (i.e., verbal learning) in these phenomena (see Table 3). There is an intimate relationship between basic cognitive abilities such as verbal learning and more complex behaviors such as coping and adaptation [1]. Such interactions may be reflected in the relationships that were observed between measures of functional capacity, choreic movements, and verbal acquisition. It is especially interesting that visual learning, and even estimated full-scale IQ, failed to correlate with any of these measures—functional capacity, chorea, or verbal learning—whereas each of the measures was significantly correlated with hypometabolism of the basal ganglia. One could speculate that a primary disability in coping and adaptation, and even in general behavioral efficiency, is based on impairment of the specific kinds of verbal ability measured in these patients.

Depression and other behavioral disturbances are known to manifest in HD. These behaviors can also adversely affect performance on tasks such as those tested here. All patients were subjectively judged by the examiner to be cooperative and motivated to participate in the studies; however, there was a lack of formal quantified measurement of affect. Also, a difference was observed between the HD and normal

groups in terms of education. The generally lower performance of the HD patients in comparison with the normal subjects could theoretically be explained on the basis of differences in education or motivation, but such factors would seem not to explain easily the correlational findings that represent the primary focus of this work. Future effort will, nevertheless, be needed to approach these intervening variables directly.

We recently presented data indicating that ^{18}F -FDG hypometabolism in cortical structures (e.g., the temporal lobes), as opposed to hypermetabolism, is associated with impaired cognitive ability [4]. In this work also, it was relative hypometabolism in the regions of interest that was associated with lowered performance. However, the observed relationships differed between the HD and normal groups. There was no significant correlation between specific cognitive abilities and brain metabolism in the normal group. This was in contrast to some very strong relationships in the HD patients. Like the HD patients, the normal subjects did evidence a strong correlation between ^{18}F -FDG metabolism in the caudate and in the putamen, but lacked such a relationship between caudate and thalamus or putamen and thalamus. It is interesting that in the one instance of a statistically significant relationship in the normal group— ^{18}F -FDG metabolism in the putamen and performance on the Digit Symbol subtest of the WAIS-R—the relationship was inverse and opposite to that found in the HD group. In the HD patients, relative hypometabolism of the putamen was found to correlate with less accurate performance on this subtest, whereas in the normal subjects better performance was related to relative hypometabolism in the putamen. Could it be that normal functional relationships between cortical and subcortical regions of brain become disrupted in a disease such as HD? To answer this question, it will be necessary to increase our understanding of the functional relationships that might exist between structures in the human brain not only under abnormal disease conditions, but in the normal state as well.

This work was supported in part by National Institutes of Health grant NS 15655.

We wish to thank the staff of the University of Michigan Cyclotron/P.E.T. facility in the Division of Nuclear Medicine.

References

1. Berent S: Psychopathology and other behavioral considerations in clinical neuropsychology. In Filskov S, Boll TJ (eds): *Handbook of Clinical Neuropsychology*, Vol 2. New York, Wiley, 1986
2. Berent S, Foster NL, Gilman S, Hichwa R: Patterns of cortical ^{18}F -FDG metabolism in Alzheimer's and progressive supranuclear palsy patients are related to the type of cognitive impairments. *Neurology* 37:172, 1987
3. Berent S, Giordani B, Young AB, et al: Positron emission to-

- mography (PET) of ^{18}F -2-fluoro-2-deoxy-D-glucose (^{18}FDG) uptake in the area of the caudate nucleus of patients with Huntington's disease: findings with the Wechsler Memory Scale. *The International Neuropsychological Society Bulletin*, November, 1984, p 5
4. Berent S, Sackellares JC, Abou-Khalil B, et al: PET studies of cerebral glucose metabolic activity in temporal lobe epilepsy: the functional implications of lateralized hypometabolism. *Neurology* 36:336, 1986
 5. Bruyn GW: Huntington's chorea: historical, clinical and laboratory synopsis. In Vinkin P, Bruyn GW (eds): *Handbook of Clinical Neurology*, Vol 6. Amsterdam, Elsevier, 1968, pp 298-378
 6. Butters N, Sax D, Montgomery K, Tarlow S: Comparison of the neuropsychological deficits associated with early and advanced Huntington's disease. *Arch Neurol* 35:585-589, 1978
 7. Caine ED, Ebert M, Weingartner H: An outline for the analysis of dementia: the memory disorder of Huntington's disease. *Neurology* 27:1087-1092, 1977
 8. Dom R, Malfroid M, Baro F: Neuropathology of Huntington's chorea: studies of the ventrobasal complex of the thalamus. *Neurology* 26:64-68, 1976
 9. Folstein SE, Jenson B, Leigh FJ, Folstein MF: The measurement of abnormal movement: methods developed for Huntington's disease. *Neurobehav Toxicol Teratol* 5:605-609, 1983
 10. Foster NL, Gilman S, Berent S, Hichwa R: Distinctive patterns of cerebral cortical glucose metabolism in progressive supranuclear palsy and Alzheimer's disease studied with positron emission tomography. *Neurology* 36:338, 1986
 11. Hayden M: *Huntington's Chorea*. Berlin, Springer Verlag, 1981
 12. Hayden MR, Martin WRW, Stoessl J, et al: The combined use of positron emission tomography (PET) and DNA polymorphisms in preclinical detection of Huntington's disease. *Am J Hum Genet* 37 (suppl 1):A58, 1985
 13. Kuhl DE, Metter EJ, Riege WH, Markham CH: Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. *Ann Neurol* 15:S119-S125, 1984
 14. Kuhl DE, Phelps ME, Markham CH, et al: Cerebral metabolism and atrophy in Huntington's disease determined by ^{18}FDG and computed tomographic scan. *Ann Neurol* 12:425-434, 1982
 15. Lange HW: Quantitative changes of telencephalon, diencephalon and mesencephalon in Huntington's chorea, postencephalitic and idiopathic parkinsonism. *Verh Anat Ges* 75:923-925, 1981
 16. Martin JB: Huntington's disease: new approaches to an old problem. *Neurology* 34:1059-1072, 1984
 17. Matsui T, Hirano A: *An Atlas of the Human Brain for Computerized Tomography*. Tokyo, Igaku-Shoin, 1978
 18. Phelps ME, Huang SC, Hoffman EJ, et al: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. *Ann Neurol* 6:371-388, 1979
 19. Phelps ME, Mazziotta JC: Positron emission tomography: human brain function and biochemistry. *Science* 228:799-809, 1985
 20. Power EG, Logue PE, McCarty SM, et al: Inter-rater reliability of the Russell revision of the Wechsler Memory Scale: an attempt to clarify some ambiguities in scoring. *J Clin Neuropsychol* 1:343-345, 1979
 21. Sanberg PR, Coyle JT: Scientific approaches to Huntington's disease. *CRC Crit Rev Clin Neurobiol* 1:1-44, 1984
 22. Seidenberg M, Giordani B, Berent S, Boll TJ: IQ level and performance on the Halstead Neuropsychological Test Battery for Children. *J Consult Clin Psychol* 51:406-413, 1984
 23. Shoulson I: Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. *Neurology* 31:1333-1335, 1981
 24. Shoulson I: Care of patients and families with Huntington's disease. In Marsden CD, Fahn S (eds): *Movement Disorders*. International Medical Review Series. London, Butterworth, 1982, pp 277-290
 25. Shoulson I: Huntington's disease: a decade of progress. *Neurol Clin* 2:515-526, 1984
 26. Shoulson I, Fahn S: Huntington's disease: clinical care and evaluation. *Neurology* 29:1-3, 1979
 27. Silverstein AB: Two- and four-subtest short forms of the WAIS-R. *J Consult Clin Psychol* 50:415-418, 1982
 28. Sokoloff L: The relationship between function and energy metabolism: its use in the localization of functional activity in the nervous system. *Neurosci Res Program Bull* 19:159-210, 1981
 29. Sweet JJ, Wysocki JJ: Improving score reliability of the Wechsler Memory Scale: a pilot study. *Clin Neuropsychol* 4:159-161, 1982
 30. Von Sattel JP, Ferrante RJ, Stevens TJ, et al: Neuropathologic classification of Huntington's disease. *J Neuropathol Exp Neurol* 44:559-577, 1985
 31. Young AB, Penney JB, Starosta-Rubinstein S, et al: PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. *Ann Neurol* 20:296-303, 1986
 32. Young AB, Shoulson I, Penney JB, et al: Huntington's disease in Venezuela: neurological features and functional decline. *Neurology* 36:244-249, 1986